Skip to content
value.today

bioAffinity Technologies, Inc.

BIAF
$5 Mmarket cap on Oct 28, 2026-61.5% since Jan 2024
Compare
World rank
#26,816
Revenue
$6 M
For year ending December-2025
Net income
$-15 M
-242.0% margin
SEC filing
Employees
—

bioAffinity Technologies, Inc. in brief

bioAffinity Technologies, Inc. is a listed company in the Diagnostics and Research industry, based in San Antonio, Texas, USA. Its market value was $5 M on 28 October 2026, which makes it the 26,816th largest listed company in the world and the 4,391st largest in the USA on this site. In the year to December 2025 it had sales of $6 M and a net loss of $15 M. Its shares trade under the symbol BIAF (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

bioAffinity Technologies, Inc. timeline

3 events, 2017–2024
  1. 2017
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2022
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 2 September 2022; shares registered for exchange trading on 23 August 2022.
  5. 2024
  6. 💰
    Record revenue of $9 million
    FY2024, the highest of the 4 years on record.

Events of bioAffinity Technologies, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$4 M$9 M$13 M$17 M2023202420252026

World rank over time

▲ up 3,445 places since 2022
2022-12-25: #30270#30,27020222023-07-30: #30235#30,23520232024-01-05: #30236#30,23620242026-03-08: #13142#13,14220262026-08-01: #23898#23,89820262026-10-14: #26568#26,56820262026-10-28: #26825#26,8252026

Rank in USA: #5,407 (Dec 2022) · #5,273 (Jul 2023) · #4,446 (Jan 2024) · #2,440 (Mar 2026) · #4,158 (Aug 2026) · #4,314 (Oct 2026) · #4,393 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.0×
Price / book
0.7×
Free cash flow yield
-174.2%
Net margin (TTM)
-279.3%
Operating margin
-171.6%
Return on equity
-211.8%
Liabilities / assets
33.6%
Revenue growth
-34.2%
R&D / revenue
22.4%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue —, net income $-6M—FY21Fiscal year ending Dec 2022: revenue $7M, net income $-8M$7MFY22Fiscal year ending Dec 2023: revenue $8M, net income $-8M$8MFY23Fiscal year ending Dec 2024: revenue $9M, net income $-9M$9MFY24Fiscal year ending Dec 2025: revenue $6M, net income $-15M$6MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$6M-34.2%$-11M$-15M-242.0%
Dec 2024$9M+18.5%$-9M$-9M-96.6%
Dec 2023$8M+14.5%$-8M$-8M-100.5%
Dec 2022$7M—$-4M$-8M-118.1%
Dec 2021——$-2M$-6M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-9M$0M$-9M$-8.66—
Dec 2024$-7M$0M$-7M$-22.50—
Dec 2023$-6M$0M$-6M$-0.91—
Dec 2022$-4M$0M$-4M$-1.81—
Dec 2021$-2M————

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$6M
Net income, trailing 12 months
$-15M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $2M, net income $-3M$2MDec ’24Three months to Mar 2025: revenue $2M, net income $-3M$2MMar ’25Three months to Jun 2025: revenue $1M, net income $-4M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $-5M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $2M, net income $-3M$2MDec ’25Three months to Mar 2026: revenue $1M, net income $-4M$1MMar ’26Three months to Jun 2026: revenue $2M, net income $-3M$2MJun ’26Three months to Sep 2026: revenue $1M, net income $-5M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (-26.2% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of bioAffinity Technologies, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$6 M
Operating income
$-11 M
Net income
$-15 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$11 M
Total liabilities
$4 M
Total equity
$7 M

As of December-2025

Top 14 institutional investors in bioAffinity Technologies, Inc.#

As of Sep 30, 2026
14 institutions held 167,559 shares (about 9.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 9.2%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 14 largest institutional investors in bioAffinity Technologies, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1HRT Financial LP91,431New5.02%$1 MNov 13, 2026
2Jane Street Group, LLC42,786New2.35%$0 MNov 12, 2026
3Virtu Financial LLC16,742New0.92%$0 MNov 17, 2026
4BlackRock, Inc.6,583New0.36%$0 MNov 13, 2026
5Vanguard Capital Management LLC3,701New0.20%$0 MNov 13, 2026
6UBS Group AG3,104New0.17%$0 MNov 10, 2026
7Vanguard Fiduciary Trust Co2,071New0.11%$0 MNov 13, 2026
8Allworth Financial LP666New0.04%$0 MNov 17, 2026
9Tower Research Capital LLC (TRC)318New0.02%$0 MNov 16, 2026
10Royal Bank Of Canada62New0.00%$0 MNov 16, 2026
11IFP Advisors, Inc55New0.00%$0 MOct 16, 2026
12Robinhood Markets, Inc.38—0.00%$0 MNov 18, 2026
13Russell Investments Group, Ltd.1New0.00%$0 MNov 6, 2026
14Pinnacle Financial Group, Inc.1—0.00%$0 MNov 16, 2026

Mutual funds holding bioAffinity Technologies, Inc.#

5 funds hold shares worth $0 M (about 5.5% of the company). Since their previous reports 3 added shares and 4 sold, selling $0 M net.
Mutual funds holding bioAffinity Technologies, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC28,059$0 M1.5%<0.01%−5.7%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.55,543$0 M3.1%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC7,639$0 M0.42%<0.01%+1575%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC6,517$0 M0.36%<0.01%+48%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC3,114$0 M0.17%<0.01%+418%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 5 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at bioAffinity Technologies, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
17
since
bioAffinity Technologies, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Timothy P. ZannesSecretary, EVP, Gen. CounselGrant or award+8,641——54,765Form 4
filed Steven GirgentiExecutive Chairman, DirectorGrant or award+14,814——1.08 MForm 4
filed James Michael EdwardsVP and CFOGrant or award+6,172——120,128Form 4
filed Maria ZannesPresident & CEO, DirectorGrant or award+37,037——280,359Form 4
filed Xavier Trinidad RevelesChief Operating OfficerGrant or award+21,604——41,943Form 4
filed James Michael EdwardsVP and CFOGrant or award+100,000——113,956Form 4
filed Maria ZannesPresident & CEO, DirectorGrant or award+33,784——243,322Form 4
filed Peter S. KnightDirectorGrant or award+33,784——117,455Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: bioAffinity Technologies, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
53,454
17.8% of shares · 1 days to cover
Reg SHO threshold list
6 days
in the last 90 days
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-10-08 16:07 UTC, code LUDP, resumed 16:17 UTC
  • 2026-09-17 16:26 UTC, code LUDP, resumed 16:31 UTC
  • 2026-09-04 15:06 UTC, code LUDP, resumed 15:11 UTC
  • 2026-09-01 13:40 UTC, code LUDP, resumed 13:45 UTC
  • 2026-08-21 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 4,980 shares at $2.96
  • : 4,301 shares at $3.51
  • : 7,605 shares at $3.63
  • : 71,087 shares at $5.64
  • : 12,551 shares at $6.56

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

bioAffinity Technologies, Inc. scorecard#

Passes 3 of the 18 checks that could be worked out: strongest in valuation (2 of 5), weakest in growth (0 of 4). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.7×Price to book 0.7× against Diagnostics and Research's median of 3.7×.
    • ✓Price to sales below its peers' median1.0×Price to sales 1.0× against Diagnostics and Research's median of 4.5×.
    • ✗Free cash flow yield above 5%-174.2%Free cash flow is -174.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 4
    • ✗Revenue grew in the newest year-34.2%Revenue down 34.2% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-3.7%-3.7% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-3.7%-3.7% a year against Diagnostics and Research's median of 3.6% (64 companies).
    • ✗Earnings per share grew in the newest year-8.66 vs -22.50Diluted EPS -8.66 in fiscal 2025 against -22.50 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$15 MNet income -$15 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-171.6%-171.6% against Diagnostics and Research's median of -2.4% (66 companies).
    • ✗Return on equity above 15%-301.8%-301.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-171.6%-171.6% in fiscal 2025 against -58.1% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.6×Current ratio 2.60 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-9.99Z-score -9.99 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year326.0%Diluted shares up 326.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from bioAffinity Technologies, Inc.'s statements, beside the median of Diagnostics and Research.

bioAffinity Technologies, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-171.6%-2.4%
Net margin-242.1%-3.6%
Return on equity-301.8%-5.4%
Revenue growth, 3 years a year-3.7%3.6%
Revenue growth-34.2%6.6%
Free cash flow margin-152.4%4.7%

4of 7on the Piotroski tests of financial strength

  • Revenue fell 34.2% against the year before.
  • Net loss of $15 million, the 5th loss-making year in a row.
  • Free cash flow was negative: -$9 million.
  • The share count rose 326.0% in the year.

bioAffinity Technologies, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

bioAffinity Technologies, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021
Income statement
Revenue6,1629,3627,9006,900r—
Cost of revenue———0.5—
Gross profit———4.3—
Research and development1,3831,4611,4681,379r1,007
Selling, general and administrative9,9149,9436,7912,481r1,069
Operating expenses16,73418,31510,5064,016r2,207
Operating income−10,573−8,953−7,973−4,011−2,207
Interest and finance income2318122470.4
Interest expense and finance costs4492372,5331,002
Other non-operating income (expense)−4,293−7557−4,141—
Income before tax−14,866−9,028−7,916−8,152−6,324
Income tax4412212.52.0
Net income including minority interests——8,6008,600—
Net income attributable to shareholders−14,910−9,040−7,937−8,154−6,326
Earnings per share, basic-8.66-22.50r-0.91-1.81-2.36
Earnings per share, diluted-8.66-22.50r-0.91-1.81—
Shares, weighted average (basic)1.70.4r8.74.52.7
Shares, weighted average (diluted)1.70.4r8.74.5—
Balance sheet
Cash and cash equivalents6,4501,1052,82211,4141,361
Receivables———10—
Inventory5428185.5—
Other current assets52042332153276
Current assets7,5652,6953,97311,9621,438
Property, plant and equipment2663754592144.6
Right-of-use (leased) assets334463370——
Goodwill1,4041,4041,404——
Other intangible assets717775833——
Total assets10,9616,5148,22212,1821,453
Accounts payable762987605345230
Current liabilities2,9063,1052,2481,13913,040
Lease liabilities (non-current)203342283——
Total liabilities3,6833,9123,3661,13913,200
Retained earnings−68,554−53,644−44,604−36,667−28,513
Shareholders' equity7,2782,6024,85511,043−15,791
Total liabilities and equity10,9616,5148,22212,1821,453
Shares outstanding0.3r0.5r9.48.42.7
Cash-flow statement
Depreciation and amortization505606250104.8
Share-based compensation67199074924943
Cash from operating activities−9,329−7,265−6,038−4,071−2,049
Capital expenditure−61−79−23−220—
Acquisitions, net of cash acquired——−2,186——
Cash from investing activities−61−79−2,209−220—
Cash from financing activities14,7345,628−34514,3443,327
Change in cash5,344−1,716−8,59210,0531,278
Report10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at bioAffinity Technologies, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 1 · Material agreement 3 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 3

bioAffinity Technologies, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementUnregistered share sale8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Delisting notice8-K
Material agreement8-K
Results announced8-K
Directors and officersShareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of bioAffinity Technologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2024$1 MPrivate placement after listingUnder $2 million3equity, optionsSEC
Mar 2024$3 MPrivate placement after listing$2 to $10 million3equity, optionsSEC
Jul 2017$4 MNo. 1$2 to $10 million39equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How bioAffinity Technologies, Inc. compares in Diagnostics and Research

  • Market cap$5 M · higher than 7% of 110
  • Revenue$6 M · higher than 12% of 123
  • Net margin-279.4% · higher than 5% of 112
  • Revenue growth-34.2% · higher than 6% of 89
  • Price / sales1.0× · lower than 88% of 85
  • Price / book0.7× · lower than 87% of 84
  • FCF yield-174.2% · higher than 0% of 66

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
bioAffinity Technologies, Inc.🇺🇸$5 M—-279.4%-34.2%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at bioAffinity Technologies, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show bioAffinity Technologies, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about bioAffinity Technologies, Inc.? Suggest a correction